&w=3840&q=100)
Will doorstep medicine delivery end? Govt panel set to take a call soon
The All-India Organisation of Chemists and Druggists, which represents around 1.24 million chemists and distributors across the country, raised strong objections, according to a report by The Economic Times.
The All-India Organisation of Chemists and Druggists (AIOCD) has urged the government to revoke a notification issued in March 2020 that permitted doorstep delivery of medicines under certain conditions, including the stamping of prescriptions. This relaxation was introduced during the Covid-19 pandemic to ensure uninterrupted access to essential medicines for patients during lockdowns.
However, the AIOCD claims the provision is now being misused by online platforms and is no longer necessary, the news report said.
Allegations of misuse by digital platforms
In a letter to Union Health Minister JP Nadda, the AIOCD expressed concern over the continued application of the notification. 'We fear with our past observations this practice of dispensing medicines without validated prescriptions appears to prioritise profit over patient welfare,' the letter said. It also specifically named platforms such as Swiggy as allegedly misusing the provision.
The Union health ministry has referred the matter to the DTAB, asking it to examine the issue and provide its recommendations. A decision is expected following deliberations at the board's upcoming meeting.
'No longer relevant', says AIOCD
According to the AIOCD, the emergency situation created by the pandemic no longer exists, making the continuation of the notification unjustified. The organisation has called for its immediate withdrawal, citing growing misuse and potential risks to patient safety.
Home delivery of medicines in India
India's home delivery of medicines has seen rapid growth, especially propelled by the Covid-19 pandemic. During the 2020 nationwide lockdown, the Central government permitted doorstep delivery of essential medicines to ensure uninterrupted access for citizens. Retailers were allowed to deliver prescription drugs directly to homes, provided customers submitted valid prescriptions physically or via email. This move was crucial for those with chronic illnesses and mobility issues, and it helped maintain drug security during a period of severe restrictions.
Delivery was managed by a combination of local pharmacies, government initiatives, and emerging online platforms.
Today, several major players dominate the home medicine delivery sector. These include Netmeds, Tata 1MG, Medlife, Apollo Pharmacy, Myra Medicines, Farmako, Pharmacy Bazar, True Meds, MediBuddy, and Healthmug.
Pincode launches 24-hour online delivery
PhonePe's hyperlocal commerce platform, Pincode — launched ahead of its parent company's planned IPO — has introduced round-the-clock online medicine delivery in Bengaluru, Mumbai, and Pune. The service includes both prescription and over-the-counter medicines.
Customers can place orders at any hour of the day, with delivery promised in just 10 minutes from the nearest participating pharmacy.
Unlike other platforms that rely on dark stores, Pincode said it has partnered directly with local chemists to fulfill orders. This model is designed to ensure faster delivery times while also helping traditional neighbourhood pharmacies grow and stay competitive in the digital economy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
25 minutes ago
- Indian Express
GMCH-32: Newly constructed block to be inaugurated on Aug 8, to decongest gynaecology dept
The newly constructed 283-bed Emergency-cum-Trauma Block at GMCH-32 is all set to be inaugurated on August 8, to coincide with the 11th convocation, promising to reduce overload on the existing emergency units in the city, improve patient care and ensure better utilisation of resources. In the hospital's history, the A Block, where 24-hour emergency services are provided to patients, was the first to become functional, and since 1996, there has been no renovation of this block. 'With the new state-of-the-art trauma block ready for patients, the first step will be to renovate the area, with the engineering and fire safety departments already in action to ensure the latest facilities, amenities and safety. Once this is complete, we will start the process of decongesting our gynaecology department, which also comprises the labour room, and witnesses patients from across the region, including the large migrant population that we have. We will be utilising this space for the expansion of the department, and also add more beds to ease rush. We are making efforts to provide more speciality and super-speciality services. The process of space creation is a dynamic one,' said Prof A K Attri, Director-Principal, GMCH-32. The gynaecology department of the hospital has 100 beds, with 10 beds added way back in 2017. The number of patients in the gynaecology department is very high, and despite the increase in beds, there are not enough beds for pregnant women. More than 5,000 women deliver in GMCH every year, and when the number of cases is higher, two women have to be adjusted on one bed, with the occupancy rate almost 200 per cent. The hospital receives delivery cases from Chandigarh, Punjab, Haryana, Himachal, Uttarakhand, UP, and despite the shortage of beds, the effort is to provide treatment. As per doctors, the gynaecology department of GMCH-32 has the highest number of deliveries, followed by GMSH-16 and then PGI. Both PGI and GMCH-32 will have exclusive Mother and Child Centres, with work on the project of GMCH-32 having started in 2018, but was delayed due to COVID and has now restarted. With a budget of about Rs 73 crore, the centre, which will be open in about two years, will have two basements and four floors and have a facility of 251 beds, with the latest facilities and services under one roof. Dr Attri said it will decrease infant and mother mortality rate. PGI's Advanced Mother and Child Care Centre, where work is in full swing and may be inaugurated at the end of this year, will be equipped with the latest technologies and offer world-class facilities in both maternal and neonatal care. A human milk bank, advanced infertility treatment, robotic surgery, critical care obstetrics, high-risk maternity unit, foetal medicine unit, pre-implantation genetic diagnosis, prenatal diagnosis, and reproductive endocrinology unit will be part of the centre. Here, there will be a modern developmentally supportive and family-centred level IV NICU designed as per current International NICU design specifications, a family-centred Kangaroo Mother Care ward, and a comprehensive high-risk follow-up programme. A long-needed facility, the Advanced Paediatric Centre at GMSH-16 was inaugurated last year. The 32-bedded facility offers state-of-the-art specialised care, featuring a 12-bedded hybrid ICU unit comprising ventilator beds and high-dependency unit beds. The centre includes 20 oxygen-supported beds and features ECG, echocardiography, and ultrasonography, all under one roof, so that parents don't have to go anywhere for these tests and their children receive the best care. There are 24-hour services like blood transfusion, sample collection, nebulisation etc, for critical patients, and this advanced centre has eased the burden on PGI.
NDTV
3 hours ago
- NDTV
Centre Flags Carcinogen Fears On Acidity Medicine Ranitidine, Orders Probe
New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has directed all state and union territory drug regulators to ensure manufacturers of Ranitidine -- a commonly used acidity medicine --monitor NDMA levels, a potentially cancer-causing impurity, in both the active pharmaceutical ingredient (API) and formulations of the drug. The CDSCO has also suggested reducing the shelf life as a precautionary step. The move comes from the Drugs Controller General of India (DCGI), Dr Rajeev Singh Raghuvanshi, following a recommendation by the Drugs Technical Advisory Board (DTAB) during its 92nd meeting on April 28, 2025. The Board reviewed a report submitted by an expert committee constituted in December last year to study the impurity concerns around Ranitidine. Based on this, DTAB has called for a larger committee to examine all aspects of the issue, including storage conditions that may contribute to NDMA formation. In addition, the Board recommended that the Indian Council of Medical Research (ICMR) conduct a study to further assess the long-term safety of Ranitidine in light of NDMA presence. Manufacturers have now been told to adopt risk-based measures, such as limiting shelf life, modifying storage recommendations, and enhancing NDMA testing protocols across their supply chains. "Ranitidine falls in the Group 2A carcinogen category, according to the International Agency for Research on Cancer (IARC), which implies that it is a probable human carcinogen. It should not be continued in prescription when there are safer alternatives such as Famotidine and Pantoprazole available," said Dr Abhishek Shankar, Oncologist, AIIMS Delhi. NDMA is classified as a probable human carcinogen, and its presence in medications has triggered global regulatory scrutiny over recent years. Ranitidine, commonly prescribed for acid reflux and ulcers, was withdrawn from several markets, including the US, after alarmingly high levels of NDMA were found in some samples. "Ranitidine was commonly prescribed in the past. Its usage has reduced in most metro cities, but it is still prescribed in Tier 1 or 2 cities, particularly at primary healthcare centres. In my knowledge, the drug has been known to have NDMA impurities; the FDA has also ruled out the use of this drug in large doses. The DGCI needs to set prescribed limits for NDMA levels in this drug," said Dr Lohit Chauhan, Gastroenterologist at Max Dwarka.
Time of India
6 hours ago
- Time of India
Far-off NEET-PG centres spark distress among aspirants; IMA-JDN urges ministry to act
New Delhi: The Indian Medical Association-Junior Doctors' Network (IMA-JDN) has submitted an urgent representation to Union Health Minister J P Nadda , raising serious concern over the allotment of NEET-PG centres. The move came after aspirants across the country reported being allotted exam centres in far-off states for the medical entrance test , triggering widespread distress and anxiety. With the National Eligibility-cum-Entrance Test-Postgraduate (NEET-PG) scheduled on August 3, the IMA-JDN has urged the Union Health Ministry to direct the National Board of Examinations in Medical Sciences (NBEMS) to reopen the exam centre change portal so that the affected candidates can avail the option of choosing centres within their home state or nearby locations. In the representation, the IMA-JDN emphasised that while some students have received centres in nearby cities, thousands of candidates have been assigned exam centres in distant states, for which they have to undertake long, expensive, and stressful journeys to unfamiliar destinations. The doctors' body said in a statement, "This move is causing much concern, especially among the economically weaker sections, ladies, and those from remote or rural regions." "This disparity not only affects fairness but could negatively impact students' mental well-being and performance in this critical, once-a-year exam," it said. "IMA-JDN remains committed to ensuring equity and accessibility in all aspects of medical education and examination systems," the doctors' body added. PTI
